Subscribe today!
Research Areas
Research Areas
Neuroscience
Cancer Research
Immunology
Infectious Disease & Vaccines
Hematology
Ophthalmology
Rare & Genetic Diseases
Dermatology
Internal Medicine
Metabolic Disease
Tools & Techniques
Regulatory & Industry
All Research Areas
News
Discovery Insider
Content
Content
Webinars
eBooks
Infographics
Videos
Articles
Industry Perspectives
Compendiums
Whitepapers
Application Notes
Magazine
All Content
Research Areas
Research Areas
Neuroscience
Cancer Research
Immunology
Infectious Disease & Vaccines
Hematology
Ophthalmology
Rare & Genetic Diseases
Dermatology
Internal Medicine
Metabolic Disease
Tools & Techniques
Regulatory & Industry
All Research Areas
News
Discovery Insider
Content
Content
Webinars
eBooks
Infographics
Videos
Articles
Industry Perspectives
Compendiums
Whitepapers
Application Notes
Magazine
All Content
Subscribe!
Subscribe Today!
Home
/
Research Areas
/
Regulatory & Industry
Regulatory & Industry
| 4 min read
By
Allison Whitten, PhD
FDA priority vouchers for GLP-1 drugs could quickly bring oral version, higher dose
Eli Lilly’s oral orforglipron and Novo Nordisk’s higher-dose WeGovy could be approved on an extremely accelerated timeline.
News
| 4 min read
By
Bree Foster, PhD
FDA compresses drug review timelines in new national priority initiative
The FDA’s National Priority Voucher program aims to cut standard review times from potentially years to months, raising questions about safety, access, and public health impact.
News
| 5 min read
By
Bree Foster, PhD
UK risks losing its lead in global pharmaceutical innovation
The life sciences sector contributes billions to the economy, but current policy and international factors are threatening growth.
News
| 3 min read
By
Bree Foster, PhD
Lilly strengthens gene therapy portfolio with MeiraGTx and Adverum deals
These latest deals give Lilly a complementary portfolio of life-changing therapies and scalable gene therapy platforms.
News
| 5 min read
By
Bree Foster, PhD
Are virtual models ready to transform early-phase drug development?
Computational models are reshaping how therapies are discovered, tested, and optimized.
News
| 5 min read
By
Bree Foster, PhD
How modeling and simulation are reshaping regulatory science
Regulatory science is increasingly relying on modeling, simulation, and AI tools to accelerate drug development while maintaining safety and efficacy.
News
Page 7 of 7 - 78 Total Items
1
2
3
4
5
6
7
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe